Zimbabwe has turned down a major American health deal valued at 367 million US dollars (272 million pounds) over five years over the United States' demand for sensitive biological samples.
The decision was revealed after a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the deal was "skewed".
An official spokesperson later stated that the US was requesting biological samples for scientific study and profit but was unwilling to share the resulting advantages from any future treatments.
"We must now begin the challenging and unfortunate task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for continued talks to reach a agreement agreeable to both sides so the country's critical HIV programme can continue.
Wider Background
This rejection comes after a comparable situation in neighbouring Kenya, where a high court suspended a related deal with the US after concerns were raised about the security of citizens' health data.
After resuming office last year, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump claimed its spending was "inefficient" and his government was seeking government-to-government agreements to boost transparency and accountability.
Based on statements, Sixteen African countries have so far signed similar agreements, constituting more than $18.3bn of fresh investment.
Details of the Rejected Agreement
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, without any corresponding promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Put simply, our country would supply the basic resources for medical research without any certainty that the end products would be available to our population should a new disease outbreak emerge."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the global health body and its push of one-on-one health agreements were upending frameworks previously set up via the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to manage future pandemics.
"This mechanism is designed to guarantee that when a nation contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to continued discussions with our US partners on how future co-operation could be designed in a manner that honours the independence and interests of each country."
Medical Community Response
A leading public health body stated it recognised the official position, but suggested that negotiations need to persist given that a large portion of the nation's Aids initiatives relied on international support.
"If technical issues exist, such as those relating to information security or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," the group said.
The halted deal underscores the continuing challenges between accepting crucial international aid and safeguarding a country's data in an increasingly data-driven world.